MD4588B1 - Compoziţii ce conţin compuşi de tiacumicină - Google Patents

Compoziţii ce conţin compuşi de tiacumicină

Info

Publication number
MD4588B1
MD4588B1 MDA20150070A MD20150070A MD4588B1 MD 4588 B1 MD4588 B1 MD 4588B1 MD A20150070 A MDA20150070 A MD A20150070A MD 20150070 A MD20150070 A MD 20150070A MD 4588 B1 MD4588 B1 MD 4588B1
Authority
MD
Moldova
Prior art keywords
compositions
tiacumicin
tiacumicin compounds
compounds
polymorph
Prior art date
Application number
MDA20150070A
Other languages
English (en)
Russian (ru)
Other versions
MD4588C1 (ro
MD20150070A2 (ro
Inventor
Ёсиюки Мураками
Хикару САИТО
Original Assignee
Astellas Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47563169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4588(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Europe Ltd filed Critical Astellas Pharma Europe Ltd
Publication of MD20150070A2 publication Critical patent/MD20150070A2/ro
Publication of MD4588B1 publication Critical patent/MD4588B1/ro
Publication of MD4588C1 publication Critical patent/MD4588C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invenţia se referă la utilizarea unui excipient, selectat din grupul format din gumă de xantan, caragenan, alginat de sodiu, gumă de guar, celuloză dispersabilă în apă (celuloză microcristalină şi carboximetilceluloză de sodiu) şi amestecuri ale acestora, în calitate de agent antispumant, într-o compoziţie ce conţine unul sau mai mulţi compuşi de tiacumicină, un stereoizomer, un polimorf sau un solvat farmaceutic acceptabil al acestora.
MDA20150070A 2013-01-15 2014-01-14 Compoziţii ce conţin compuşi de tiacumicină MD4588C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13075002 2013-01-15
PCT/EP2014/000091 WO2014111254A1 (en) 2013-01-15 2014-01-14 Composition of tiacumicin compounds

Publications (3)

Publication Number Publication Date
MD20150070A2 MD20150070A2 (ro) 2016-01-31
MD4588B1 true MD4588B1 (ro) 2018-08-31
MD4588C1 MD4588C1 (ro) 2019-03-31

Family

ID=47563169

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150070A MD4588C1 (ro) 2013-01-15 2014-01-14 Compoziţii ce conţin compuşi de tiacumicină

Country Status (28)

Country Link
US (1) US9808530B2 (ro)
EP (1) EP2945613B1 (ro)
JP (1) JP6338598B2 (ro)
KR (1) KR102181474B1 (ro)
CN (1) CN105120840B (ro)
AR (1) AR094495A1 (ro)
AU (1) AU2014207083B2 (ro)
CA (1) CA2904808A1 (ro)
CY (1) CY1121459T1 (ro)
DK (1) DK2945613T3 (ro)
EA (1) EA030049B1 (ro)
ES (1) ES2705238T3 (ro)
GE (1) GEP201706769B (ro)
HR (1) HRP20182110T1 (ro)
HU (1) HUE041421T2 (ro)
IL (1) IL239899A0 (ro)
JO (1) JO3464B1 (ro)
LT (1) LT2945613T (ro)
MD (1) MD4588C1 (ro)
NZ (1) NZ710875A (ro)
PL (1) PL2945613T3 (ro)
PT (1) PT2945613T (ro)
RS (1) RS58119B1 (ro)
SI (1) SI2945613T1 (ro)
TW (1) TWI646962B (ro)
UA (1) UA117004C2 (ro)
WO (1) WO2014111254A1 (ro)
ZA (1) ZA201505048B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137141B2 (en) * 2014-05-09 2018-11-27 Astellas Pharma Europe Ltd. Treatment regimen tiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
CA2384523C (en) 1991-03-04 2007-01-09 Bayer Corporation Automated analyzer
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
KR20070092334A (ko) 2000-04-28 2007-09-12 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
JP2005534332A (ja) 2002-07-29 2005-11-17 オプティマー ファーマシューティカルズ、インコーポレイテッド チアクマイシン生産
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP4640821B2 (ja) 2003-07-24 2011-03-02 塩野義製薬株式会社 難水溶性薬物を含むドライシロップ剤
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
PL2070530T3 (pl) 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
JP5166040B2 (ja) 2005-01-31 2013-03-21 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
AU2006304868B2 (en) 2005-10-21 2013-02-21 Merck Sharp & Dohme Corp. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP5608880B2 (ja) * 2010-02-09 2014-10-22 林兼産業株式会社 嚥下困難者用高栄養ゼリー食品
CN102030791B (zh) 2010-10-28 2013-01-23 中国科学院南海海洋研究所 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用

Also Published As

Publication number Publication date
DK2945613T3 (en) 2019-01-14
IL239899A0 (en) 2015-08-31
ZA201505048B (en) 2020-05-27
AR094495A1 (es) 2015-08-05
CN105120840A (zh) 2015-12-02
PT2945613T (pt) 2019-01-17
AU2014207083B2 (en) 2018-03-29
HRP20182110T1 (hr) 2019-02-22
MD4588C1 (ro) 2019-03-31
MD20150070A2 (ro) 2016-01-31
ES2705238T3 (es) 2019-03-22
HUE041421T2 (hu) 2019-05-28
EP2945613A1 (en) 2015-11-25
AU2014207083A1 (en) 2015-08-27
JO3464B1 (ar) 2020-07-05
KR20150114498A (ko) 2015-10-12
EP2945613B1 (en) 2018-10-10
JP2016505026A (ja) 2016-02-18
TW201440775A (zh) 2014-11-01
NZ710875A (en) 2019-10-25
EA030049B1 (ru) 2018-06-29
PL2945613T3 (pl) 2019-05-31
TWI646962B (zh) 2019-01-11
EA201591226A1 (ru) 2016-01-29
LT2945613T (lt) 2019-01-10
CY1121459T1 (el) 2020-05-29
US20160045603A1 (en) 2016-02-18
CN105120840B (zh) 2019-03-22
RS58119B1 (sr) 2019-02-28
KR102181474B1 (ko) 2020-11-23
SI2945613T1 (sl) 2019-02-28
GEP201706769B (en) 2017-11-10
US9808530B2 (en) 2017-11-07
JP6338598B2 (ja) 2018-06-06
CA2904808A1 (en) 2014-07-24
WO2014111254A1 (en) 2014-07-24
UA117004C2 (uk) 2018-06-11

Similar Documents

Publication Publication Date Title
NZ747259A (en) Soluble c5ar antagonists
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2015011520A (es) Composiciones antimicrobianas.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD20160012A2 (ro) Formulare de inhibitori SYK
JO3773B1 (ar) معدلات p2x7
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
GEP20227397B (en) Inhibitors of influenza viruses replication
MX348823B (es) Formulaciones estables de linaclotida.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12014502696A1 (en) High water content oral compositions comprising microcrystalline cellulose and carboxymethylcellulose
UA115357C2 (uk) Похідні піридин-4-ілу
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MD4588B1 (ro) Compoziţii ce conţin compuşi de tiacumicină
IN2013MU03309A (ro)
IN2013MU03308A (ro)
IN2013MU03565A (ro)
IN2013MU03422A (ro)
MY178005A (en) High water content oral compositions comprising microcrystalline cellulose and carboxymethylcellulose

Legal Events

Date Code Title Description
FG4A Patent for invention issued
PD4A Change of proprietorship (patent for invention)

Owner name: TILLOTTS PHARMA AG, CH

Free format text: PREVIOUS PROPRIETOR: ASTELLAS PHARMA EUROPE LTD, GB STR. 2000 HILLSWOOD DRIVE CHERTSEY, SURREY KT16 0RS, REGATUL UNIT, MAREA BRITANIE